LCZ696 (Sacubitril + Valsartan)

Nkọwa dị mkpirikpi:

Aha API Ngosipụta Nkọwapụta US DMF EU DMF CEP
LCZ696 (Sacubitril + Valsartan) Obi mgbawa N'ime ụlọ    


Nkọwa ngwaahịa

Mkpado ngwaahịa

Nkọwa ngwaahịa

Nkọwa

LCZ696 (Sacubitril/Valsartan), nke gụnyere Valsartan (ARB) na Sacubitril (AHU377) na 1: 1 molar ratio, bụ nke mbụ na klaasị, ọnụ ọnụ bioavailable, na dual-eme angiotensin receptor-neprilysin (ARN) inhibitor maka ọbara mgbali elu. na nkụda mmụọ obi[1][2][3]. LCZ696 na-emeziwanye cardiomyopathy ọrịa shuga site na igbochi mbufụt, nrụgide oxidative na apoptosis.

 

ndabere

LCZ696 bụ nke mbụ na klaasị ARNi (angiotensin receptor neprilysin inhibitor) nke gụnyere moieties anionic nke AR valsartan na neprilysin inhibitor prodrug AHU377 (1: 1 ratio) maka nkụda obi na ọbara mgbali elu.

Ndị na-anabata angiotensin bụ G-protein jikọtara ọnụ. Ha na-agbazi usoro obi na arịa ndị ọzọ nke angiotensin II nke bụ peptide bioactive nke sistemu renin-angiotensin. Neprilysin bụ endopeptidase na-anọpụ iche nke na-eweda peptides endogenous vasoactive dị ka peptides natriuretic. Mgbochi nke neprilysin na-abawanye mkpokọta peptides natriuretic nke nyere aka na nchekwa obi, vaskụla na akụrụ. [1]

Na oke Sprague-Dawley, nchịkwa ọnụ nke LCZ696 mere ka mmụba dabere na dose na immunoreactivity nke peptide atrial natriuretic nke sitere na mgbochi neprilysin. N'ime oke oke transgenic okpukpu abụọ nke hypertensive, LCZ696 kpatara mbelata nke dabere na dose na nkwụsi ike na nrụgide akwara. Ndị sonyere na ahụike, nyocha nke enweghị usoro, kpuru ìsì abụọ, ebe a na-achịkwa ebebo gosipụtara na LCZ696 nyere mgbochi neprilysin na-emekọ ihe na mgbochi nnabata AT1. LCZ696 dị mma yana nnabata nke ọma n'ime mmadụ. [2] [3]

Ntụaka:
McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition na enalapril na nkụda obi. N Engl J Med. 2014 Sep 11;371(11):993-1004 .
Gu J, Noe A, Chandra P, Al-Fayoumi S et al. Pharmacokinetics na pharmacodynamics nke LCZ696, akwụkwọ akụkọ abụọ na-eme angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Eprel; 50 (4): 401-14 .
Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition na LCZ696: usoro ọhụụ maka ọgwụgwọ nke nkụda obi, Drug Discov Taa: Ther Strategies (2014)

 

Nchekwa

Ntụ ntụ

-20°C

Afọ 3
 

4°C

afọ 2
Na ihe mgbaze

-80 Celsius

Ọnwa isii
 

-20°C

1 ọnwa

Ọdịdị chemical

LCZ696 (Sacubitril + Valsartan)

Asambodo

2018 GMP-2
原料药GMP证书201811 (captopril, thalidomide wdg)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
Akwụkwọ ozi FDA-EIR-201901

njikwa mma

Njikwa ogo1

Atụmatụ18Arụmọrụ ntule na-agbanwe agbanwe nke akwadoro4, na6oru ngo na-akwado.

Njikwa ogo2

Usoro njikwa ogo mba ụwa dị elu etinyela ntọala siri ike maka ire ahịa.

njikwa mma3

Nlekọta dị mma na-aga n'ihu na usoro ndụ nke ngwaahịa ahụ niile iji hụ na ịdị mma na mmetụta ọgwụgwọ.

Njikwa ogo4

Ndị otu Regulatory Affairs ndị ọkachamara na-akwado ịdịmma chọrọ n'oge ngwa na ndebanye aha.

njikwa mmepụta

cpf5
cpf6

Ahịrị nkwakọ ngwaahịa Korea Countec

cpf7
cpf8

Taiwan CVC ahịrị nkwakọ ngwaahịa

cpf9
cpf10

Line CAM Board nke Italy

cpf11

Igwe na-agbakọ Fette German

cpf12

Ihe nchọpụta mbadamba ihe ngosi nke Japan

cpf14-1

Ụlọ njikwa DCS

Onye mmekọ

Mmekọrịta mba ụwa
Mmekọrịta mba ụwa
Imekọ ihe ọnụ n'ụlọ
Imekọ ihe ọnụ n'ụlọ

  • Nke gara aga:
  • Osote:

  • Dee ozi gị ebe a ziga anyị ya

    Ụdị ngwaahịa